Article Complication Engineering Screening 
FDA Law Blog
DECEMBER 6, 2023
The support FDA offers for its proposition – which comes from a mixture of sources, including a few published scientific articles, newspaper stories, FDA’s experience with LDTs with COVID, anecdotes, older case studies, and class action lawsuits – is singularly unconvincing. The proposed rule similarly ignores the benefits of LDTs.
Medical Xpress
JUNE 16, 2025
Edwards edited by Gaby Clark , reviewed by Andrew Zinin Gaby Clark scientific editor Meet our editorial team Behind our editorial process Andrew Zinin lead editor Meet our editorial team Behind our editorial process Editors notes This article has been reviewed according to Science Xs editorial process and policies.
Expert insights. Personalized for you.
59 
Let's personalize your content